Ironwood Pharmaceuticals, Inc. (IRWD)

Ironwood Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	338.99	351.41	442.74	410.6	413.75	389.52
Revenue Growth (YoY)	-10.42%	-20.63%	7.83%	-0.76%	6.22%	-9.08%
Cost of Revenue	-5.21	7.55	6.15	4.94	70.41	91.2
Gross Profit	344.19	343.86	436.59	405.66	343.35	298.33
Selling, General & Admin	96.55	144.27	142.11	115.99	111.13	140
Research & Development	103.87	103.87	98.64	39.33	-	-
Operating Expenses	200.42	248.14	240.75	155.32	111.13	140
Operating Income	143.77	95.72	195.84	250.34	232.22	158.32
Interest Expense	-33.78	-33.29	-21.38	-7.6	-31.15	-29.48
Interest & Investment Income	3.4	4.47	18.97	9.5	0.73	1.5
Other Non Operating Income (Expenses)	0.76	0.89	-0.23	0.18	-1.18	-6.11
EBT Excluding Unusual Items	114.15	67.79	193.2	252.42	200.61	124.24
Merger & Restructuring Charges	-20.58	-2.59	-45.82	-	0.04	-15.38
Pretax Income	93.57	65.2	-948.07	252.42	200.66	108.86
Income Tax Expense	65.02	64.32	83.49	77.36	-327.79	2.69
Earnings From Continuing Operations	28.55	0.88	-1,032	175.07	528.45	106.18
Net Income to Company	28.55	0.88	-1,032	175.07	528.45	106.18
Minority Interest in Earnings	-	-	29.32	-	-	-
Net Income	28.55	0.88	-1,002	175.07	528.45	106.18
Net Income to Common	28.55	0.88	-1,002	175.07	528.45	106.18
Net Income Growth	-	-	-	-66.87%	397.71%	393.73%
Shares Outstanding (Basic)	161	159	155	154	162	159
Shares Outstanding (Diluted)	174	160	155	186	164	161
Shares Change (YoY)	9.90%	2.99%	-16.57%	13.32%	2.34%	2.97%
EPS (Basic)	0.18	0.01	-6.45	1.13	3.26	0.67
EPS (Diluted)	0.18	0.01	-6.45	0.96	3.21	0.66
EPS Growth	-	-	-	-69.98%	386.36%	378.84%
Free Cash Flow	67.65	103.41	183.15	273.63	261.63	166.99
Free Cash Flow Per Share	0.39	0.65	1.18	1.47	1.59	1.04
Gross Margin	101.53%	97.85%	98.61%	98.80%	82.98%	76.59%
Operating Margin	42.41%	27.24%	44.23%	60.97%	56.12%	40.64%
Profit Margin	8.42%	0.25%	-226.37%	42.64%	127.72%	27.26%
Free Cash Flow Margin	19.96%	29.43%	41.37%	66.64%	63.23%	42.87%
EBITDA	145.68	97.73	197.41	251.76	233.74	160.69
EBITDA Margin	42.97%	27.81%	44.59%	61.31%	56.49%	41.25%
D&A For EBITDA	1.91	2.01	1.58	1.42	1.52	2.36
EBIT	143.77	95.72	195.84	250.34	232.22	158.32
EBIT Margin	42.41%	27.24%	44.23%	60.97%	56.12%	40.64%
Effective Tax Rate	69.49%	98.65%	-	30.65%	-	2.47%
Revenue as Reported	338.99	351.41	442.74	410.6	413.75	389.52

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q